I 116th CONGRESS 2d Session H. R. 7025 IN THE HOUSE OF REPRESENTATIVES May 27, 2020 Mr. Bucshon introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Public Health Service Act to authorize grants to certain public health laboratories to assist such laboratories in meeting the cost of acquiring high-throughput diagnostic equipment, and for other purposes.

1. Short title This Act may be cited as the Diagnostic Testing for Public Health Labs Act of 2020 . 2. Grants for public health laboratories to acquire high-throughput diagnostic equipment Section 2821 of the Public Health Service Act ( 42 U.S.C. 300hh–31 ) is amended— (1) by redesignating subsection (b) as subsection (c); (2) in subsection (c), as so redesignated— (A) by redesignating paragraphs (1), (2), and (3) as subparagraphs (A), (B), and (C), respectively, and moving the margin of each such redesignated subparagraph 2 ems to the right; and (B) by striking There are authorized to be appropriated to carry out this section and inserting the following: (1) In general There are authorized to be appropriated to carry out subsection (a) ; (3) by inserting after subsection (a) the following new subsection: (b) Grants for public health laboratories to acquire high-Throughput diagnostic equipment (1) Grants The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall award grants to eligible entities to assist such entities in purchasing high-throughput diagnostic equipment and related supplies. (2) Eligibility To be eligible for a grant under paragraph (1), an entity shall— (A) be— (i) a State, local, or Tribal public health laboratory; (ii) a laboratory within a public health laboratory network coordinated or managed by the Centers for Disease Control and Prevention; (iii) a laboratory not described in clause (i) or (ii) that the Secretary determines (at the Secretary’s discretion) provides population-based testing for the prevention and control of infectious, communicable, genetic, or chronic diseases; or (iv) a consortium of 2 or more entities described in any of clauses (i) through (iii); and (B) submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may reasonably require. (3) Use of funds Amounts received through a grant under this subsection shall be used to purchase high-throughput diagnostic equipment and such materials as are necessary to administer, store, and process applicable tests, including diagnostic and serological tests. (4) Amount of grant The amount of a grant under paragraph (1) may not exceed $2,000,000, except in the case of eligible entity described in paragraph (2)(A)(iv). (5) High-throughput diagnostic equipment defined In this subsection, the term high-throughput diagnostic equipment means legally-marketed equipment and supplies capable of performing multichannel analysis for use in clinical laboratory diagnostic testing. ; and (4) by adding at the end of subsection (c), as redesignated, the following new paragraph: (2) Authorization of appropriations (A) In general For the purpose of carrying out subsection (b), there is authorized to be appropriated $250,000,000 for fiscal year 2020, to remain available until expended. (B) Administrative expenses Of the amount made available to carry out subsection (b) for any fiscal year, the Secretary may not use more than 5 percent of such amount for the expenses of administering subsection (b). .